TY - JOUR
T1 - Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer
AU - Hiroshima, Yukihiko
AU - Nakamura, Fumio
AU - Miyamoto, Hiroshi
AU - Mori, Ryutaro
AU - Taniguchi, Koichi
AU - Matsuyama, Ryusei
AU - Akiyama, Hirotoshi
AU - Tanaka, Kuniya
AU - Ichikawa, Yasushi
AU - Kato, Shingo
AU - Kobayashi, Noritoshi
AU - Kubota, Kensuke
AU - Nagashima, Yoji
AU - Goshima, Yoshio
AU - Endo, Itaru
PY - 2013
Y1 - 2013
N2 - Background. Pancreatic cancer is an aggressive malignancy with one of the worst mortality rates of all cancers. Recently, collapsin response mediator proteins (CRMPs) were reported to be associated with proliferation, apoptosis, differentiation, and invasion in several cancers. However, CRMP expression and their role in pancreatic cancer have not been investigated. This study aimed to clarify the clinical significance of CRMPs in pancreatic cancer. Methods. Expression of crmp genes in 11 pairs of pancreatic cancer and corresponding noncancerous pancreas tissues were examined by real-time RT-PCR. Knockdown of CRMP4 expression using siRNA was examined in pancreatic cancer cell lines to determine whether CRMP4 regulates cell proliferation and invasion in vitro. Furthermore, CRMP4 protein levels in primary tumors of pancreatic cancer (n = 53) were examined by immunohistochemistry and compared with the clinicopathological features of the tumors. Results. Of all the CRMPs, only CRMP4 was differentially expressed in pancreatic cancer tissues (p = 0.008). CRMP4 knockdown using siRNA reduced cellular invasion, but did not affect proliferation. The expression of CRMP4 was detected immunohistochemically in 34 (64.2 %) of the 53 pancreatic cancer samples, and CRMP4 expression was correlated with severe venous invasion (p = 0.044), stage (p = 0.019), and liver metastasis (p = 0.021). Multivariate analyses suggested that venous invasion and CRMP4 overexpression were prognostic factors for survival. Conclusions. Our results suggested that CRMP4 is significantly associated with poor prognosis by promoting liver metastasis and can serve as a novel therapeutic target for pancreatic cancer.
AB - Background. Pancreatic cancer is an aggressive malignancy with one of the worst mortality rates of all cancers. Recently, collapsin response mediator proteins (CRMPs) were reported to be associated with proliferation, apoptosis, differentiation, and invasion in several cancers. However, CRMP expression and their role in pancreatic cancer have not been investigated. This study aimed to clarify the clinical significance of CRMPs in pancreatic cancer. Methods. Expression of crmp genes in 11 pairs of pancreatic cancer and corresponding noncancerous pancreas tissues were examined by real-time RT-PCR. Knockdown of CRMP4 expression using siRNA was examined in pancreatic cancer cell lines to determine whether CRMP4 regulates cell proliferation and invasion in vitro. Furthermore, CRMP4 protein levels in primary tumors of pancreatic cancer (n = 53) were examined by immunohistochemistry and compared with the clinicopathological features of the tumors. Results. Of all the CRMPs, only CRMP4 was differentially expressed in pancreatic cancer tissues (p = 0.008). CRMP4 knockdown using siRNA reduced cellular invasion, but did not affect proliferation. The expression of CRMP4 was detected immunohistochemically in 34 (64.2 %) of the 53 pancreatic cancer samples, and CRMP4 expression was correlated with severe venous invasion (p = 0.044), stage (p = 0.019), and liver metastasis (p = 0.021). Multivariate analyses suggested that venous invasion and CRMP4 overexpression were prognostic factors for survival. Conclusions. Our results suggested that CRMP4 is significantly associated with poor prognosis by promoting liver metastasis and can serve as a novel therapeutic target for pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84892815403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892815403&partnerID=8YFLogxK
U2 - 10.1245/s10434-012-2491-3
DO - 10.1245/s10434-012-2491-3
M3 - Article
C2 - 22805864
AN - SCOPUS:84892815403
SN - 1068-9265
VL - 20
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 3 SUPPL.
ER -